QUINTA-ANALYTICA
Pavel Berka has a Ph.D. in Farmaceutická technologie from Charles University and a Mgr. in Farmacie. Currently working as an HPLC analyst in the Highly Potent Substances Laboratory at QUINTA-ANALYTICA since April 2021. Previously held roles as Head of QC laboratory and QC Manager at InStar Technologies a.s. Also worked as an Akademický pracovník AP1 – asistent na katedře farmaceutické technologie at Charles University and as a Research Fellow at King's College London.
QUINTA-ANALYTICA
Quinta is a GCP/GLP/GMP-certified, EMA and FDA-inspected European CRO offering in-house clinical testing, pharmaceutical analysis, CMC and R&D. Quinta specializes in clinical studies, bioanalytics, method development and quality control for both small and large molecules, human and veterinary IMPs as well as generics. We provide unrivaled expertise to worldwide pharmaceutical and biotechnological clients across the entire pharma spectrum. Quinta is part of the Conscio group with headquarters in Munich, Germany, laboratories in Czechia, Austria, Slovakia, Germany and offices in the USA. Our main service areas include: 1) Clinical Testing: With 2 in-house clinical units providing BE/BA/PK studies, with capacity for 60+40 beds. 2) Bioanalytical Testing: GLP/GCP solutions for preclinical & clinical studies, small & large molecules, BE/BA/PK. 3) Research & Development: Analytical R&D, impurities, extractables & leachables, degradation, trace studies. 4) Pharmaceutical Quality Control: GMP quality control, batch testing, stabilities, HAPIs, inhalation, API sourcing. 5) Microbiology: GMP sterile & non-sterile testing, microbial/water analyses, endotoxins, antibiotics & vitamins. 6) Biopharmaceutical Quality Control: GLP/GMP bioanalysis, CMC, characterizations of peptide & protein IMPs, biosimilars. Quinta was founded in 1997 and has been successfully inspected by FDA more than 10 times. Quinta is headquartered in Prague, Czech Republic.